Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25 billion, that ...
Hosted on MSN
Analysts eye biotech M&A as $300B patent cliff nears
A looming $300 billion patent cliff by 2030 is spurring a surge in biotech M&A, with March 2026 alone seeing $31.5 billion in deals. Analysts highlight CRISPR Therapeutics, Intellia Therapeutics, and ...
Stocktwits on MSN
Cathie Wood's ARK bets bigger on this biotech play, slashes stake in this space stock
The firm has been steadily adding NTLA stock across its ETFs throughout 2026, with repeated purchases in January, February, March, and now April. ・RKLB stock’s sale marks ARK’s second offload this ...
A British newspaper recently claimed that criminals might be able to manipulate their own DNA to dodge police detection.
13h
Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could ...
This manuscript has convincing data that provides a high-resolution structure of the Egl-RNA complex. The findings are important to understand the formation, stability, and interactions of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results